<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989493</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1009</org_study_id>
    <secondary_id>R01AA024388</secondary_id>
    <secondary_id>A487400</secondary_id>
    <secondary_id>L&amp;S\PSYCHOLOGY\PSYCHOLOGY</secondary_id>
    <secondary_id>Protocol Version 11/7/2019</secondary_id>
    <nct_id>NCT02989493</nct_id>
  </id_info>
  <brief_title>Testing Doxazosin to Treat Stress Mechanisms in Alcoholism</brief_title>
  <official_title>Randomized Controlled Trial Targeting Noradrenergic Stress Mechanisms in Alcoholism With Doxazosin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, placebo controlled, randomized controlled trial (RCT) for Alcohol Use Disorder&#xD;
      examining the effects of doxazosin, a norepinephrine alpha1 receptor antagonist, on stress&#xD;
      reactivity and clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        1. To translate the preclinical evidence from animal models to stress-induced relapse in&#xD;
           humans via direct pharmacological antagonism of the noradrenergic system in abstinent&#xD;
           alcoholics with doxazosin, an alpha1 noradrenergic receptor blocker.&#xD;
&#xD;
        2. To screen the efficacy of doxazosin to target stress-related relapse mechanisms in&#xD;
           abstinent alcoholics as a cost-effective first step to repurpose this alpha1&#xD;
           noradrenergic antagonist for relapse prevention in addiction.&#xD;
&#xD;
      PARTICIPANTS:&#xD;
&#xD;
      136 participants with an Alcohol Use Disorder in early abstinence.&#xD;
&#xD;
      STUDY OVERVIEW:&#xD;
&#xD;
      136 adults with an Alcohol Use Disorder in early abstinence (1-8 weeks abstinent) will&#xD;
      participate in a randomized controlled trial (RCT) to examine the efficacy of 8 mg doxazosin&#xD;
      (vs. placebo, between-subjects) on stress reactivity and clinical outcome measures (e.g.,&#xD;
      drinks/week, alcohol craving) during a 8 week treatment period. Doxazosin's impact on&#xD;
      stress-related relapse mechanisms will be assessed using a well-validated human model of&#xD;
      stressor reactivity (No Shock, Predictable Shock, Unpredictable Shock [NPU] task) at baseline&#xD;
      (pre-treatment) and after 4 weeks of treatment. The NPU task has strong translational ties to&#xD;
      both methods (e.g., unpredictable vs. predictable electric shock) and measures (e.g., startle&#xD;
      potentiation) from the preclinical literature in animals. This laboratory stress task serves&#xD;
      as an attractive early surrogate endpoint post-treatment to assess treatment efficacy and&#xD;
      examine stress mechanisms.&#xD;
&#xD;
      AIMS and HYPOTHESIS:&#xD;
&#xD;
      AIM 1: Examine effects of a therapeutic dose of doxazosin on responses to unpredictable&#xD;
      stressors in NPU task. The aim is to obtain preliminary evidence via a laboratory surrogate&#xD;
      endpoint to repurpose doxazosin for the treatment of stress-induced relapse mechanisms in&#xD;
      alcoholism.&#xD;
&#xD;
      PREDICTIONS: Following four weeks of therapeutic dosing, doxazosin (8 mg vs. placebo,&#xD;
      between-subjects) will selectively reduce response to unpredictable (vs. predictable)&#xD;
      stressors indexed by physiological defensive reactivity (startle potentiation) and&#xD;
      self-reported negative affect and craving in abstinent alcoholics.&#xD;
&#xD;
      AIM 2: Examine effects of a therapeutic dose of doxazosin on early clinical outcome measures.&#xD;
      The aim is to obtain additional evidence via clinical outcome measures to repurpose doxazosin&#xD;
      for the treatment of stress-induced relapse mechanisms in alcoholism.&#xD;
&#xD;
      PREDICTIONS: Following eight weeks of therapeutic dosing, doxazosin (8 mg vs. placebo,&#xD;
      between-subjects) will increase continuous abstinence and decrease drinking days per week and&#xD;
      drinks per week during the medication treatment period. Doxazosin will also decrease craving&#xD;
      measured during the 8th week of medication use when participants have achieved the maximum&#xD;
      dose for 4.5 weeks.&#xD;
&#xD;
      AIM 3: Examine predictive validity of pre-treatment laboratory tests of noradrenergic&#xD;
      relevant stress-reactivity on surrogate endpoint and clinical outcome measures. The aim is to&#xD;
      link individual differences in stress reactivity at baseline (i.e. pre-treatment) to&#xD;
      laboratory surrogate endpoints and early clinical outcome measures following therapeutic&#xD;
      dosing.&#xD;
&#xD;
      PREDICTIONS: Higher pre-treatment reactivity during unpredictable stressors will predict&#xD;
      poorer surrogate endpoint and clinical outcomes overall. Therapeutic 8 mg dose effects of&#xD;
      doxazosin will be greater among alcoholics who display higher pre-treatment reactivity to&#xD;
      unpredictable stressors.&#xD;
&#xD;
      AIM 4: Examine if the effects of doxazosin on clinical outcome measures are mediated by a&#xD;
      reduction of stress-reactivity as measured by the NPU task. The aim is to identify whether&#xD;
      reductions in stress-reactivity (NPU task) is the mechanism through which doxazosin has its&#xD;
      effect on drinking behavior (clinical outcome).&#xD;
&#xD;
      PREDICTIONS: The direct effect of doxazosin (vs. placebo) following 8 weeks of therapeutic 8&#xD;
      mg dosing on clinical outcomes (e.g., continuous abstinence, drinking days/week, drinks/week)&#xD;
      will be partially mediated by the indirect effect of doxazosin on surrogate endpoint of NPU&#xD;
      stress reactivity at 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Actual">March 13, 2020</completion_date>
  <primary_completion_date type="Actual">March 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Startle Potentiation During Stress Reactivity Task</measure>
    <time_frame>4 weeks</time_frame>
    <description>Startle potentiation is used to study anxiety and fear with No-shock, Predictable-shock, Unpredictable-shock (NPU) task; a common, well-validated laboratory stressor task. In the Predictable condition of the NPU task, shocks are 100 percent predictable and occur at a consistent, known time. In the Unpredictable condition of the NPU task, shocks are fully unpredictable. A higher score on startle potentiation means a higher stress reactivity response for the given condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Any Heavy Drinking Days</measure>
    <time_frame>8 weeks</time_frame>
    <description>Timeline-followback (TLFB) was administered twice at 4 weeks and 8 weeks. Participants reported the number of drinks per day for each previous 30 day period. Any heavy drinking was scored &quot;yes&quot; if participant reported any days of heavy drinking (&gt; 4/3 standard drinks for men/women) during the total 8 week assessment period; &quot;no&quot; if no heavy drinking was reported</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Doxazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 8 weeks of doxazosin (8mg target dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 8 weeks of matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>Doxazosin</description>
    <arm_group_label>Doxazosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Diagnostic and Statistical Manual (DSM-5) diagnosis of Alcohol Use Disorder,&#xD;
             Moderate-Severe&#xD;
&#xD;
          -  Alcohol abstinent for 1 - 8 weeks&#xD;
&#xD;
          -  Ages of 18 to 65&#xD;
&#xD;
        Exclusion criteria are divided into three broad categories of Medical,&#xD;
        Psychiatric/Behavioral, and Medications/Therapies.&#xD;
&#xD;
        EXCLUSION CRITERIA: Medical&#xD;
&#xD;
          -  Blood alcohol concentration above 0.00.&#xD;
&#xD;
          -  Color blind.&#xD;
&#xD;
          -  Heart rate &gt;100 beats per minute after five minutes seated.&#xD;
&#xD;
          -  Heart rate &lt;55 beats per minute after five minutes seated.&#xD;
&#xD;
          -  Systolic BP &lt;100 after five minutes seated.&#xD;
&#xD;
          -  Systolic BP drop &gt;20mm Hg or diastolic BP drop &gt;10mm Hg after two minutes standing.&#xD;
&#xD;
          -  Dizziness, lightheadedness, unsteadiness or other problems (e.g, nausea, blurry&#xD;
             vision) after two minutes standing.&#xD;
&#xD;
          -  Uncorrected auditory/vision problems.&#xD;
&#xD;
          -  Current treatment for chronic pain condition.&#xD;
&#xD;
          -  Past or current coronary artery disease, cerebrovascular accident, congestive heart&#xD;
             failure.&#xD;
&#xD;
          -  Current chronic renal insufficiency, liver insufficiency or moderate hepatic&#xD;
             impairment, pancreatitis, immunosuppressive therapy, or cancer with systemic effects&#xD;
             or therapy.&#xD;
&#xD;
          -  Benign positional vertigo, Meniere's disease, or narcolepsy.&#xD;
&#xD;
          -  Previous allergic or adverse reaction to doxazosin or other alpha1 noradrenergic&#xD;
             antagonist.&#xD;
&#xD;
          -  Scheduled or reported plans for cataract surgery prior to study completion.&#xD;
&#xD;
          -  Currently symptomatic of alcohol withdrawal [Clinical Institute Withdrawal Assessment&#xD;
             for Alcohol, revised (CIWA-Ar) Score &gt; 10, or positive for any 'visual, auditory or&#xD;
             tactile disturbances,' or for 'orientation and clouding of sensorium']&#xD;
&#xD;
          -  Discharged from inpatient treatment for Alcohol Use Disorder or alcohol detoxification&#xD;
             within past 7 days.&#xD;
&#xD;
          -  Currently medically unstable.&#xD;
&#xD;
          -  Electrocardiogram (ECG) clinical over-read indicates concerns of cardiac function.&#xD;
&#xD;
          -  Other self-reported acute or unstable illness that, in the opinion of the study team,&#xD;
             would preclude a safe and reliable study participation&#xD;
&#xD;
        EXCLUSION CRITERIA: Female Participants Only&#xD;
&#xD;
          -  Non-negative urine pregnancy test.&#xD;
&#xD;
          -  Women of childbearing potential (see definition below) must agree to use one of the&#xD;
             following forms of birth control until after study completion. Acceptable birth&#xD;
             control is defined as the following methods of contraception: abstinence; hormonal&#xD;
             contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables,&#xD;
             and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy of&#xD;
             partner and tubal ligation; &quot;single&quot; barrier methods of contraception (e.g. male&#xD;
             condom, female condom, cervical cap, diaphragm, contraceptive sponge) with use of&#xD;
             spermicide; or &quot;double barrier&quot; method of contraception (e.g. male condom with&#xD;
             diaphragm, male condom with cervical cap).&#xD;
&#xD;
          -  Breastfeeding.&#xD;
&#xD;
        NOTE: Women of childbearing potential are females who have experienced menarche and do not&#xD;
        meet the criteria for women not of childbearing potential. Women not of childbearing&#xD;
        potential are females who are permanently sterile (e.g., hysterectomy, bilateral&#xD;
        oophorectomy) or postmenopausal. Postmenopausal is defined as 12 consecutive months with no&#xD;
        menses without an alternative medical cause.&#xD;
&#xD;
        EXCLUSION CRITERIA: Psychological/Behavioral&#xD;
&#xD;
          -  Self-reported lifetime diagnosis of schizophrenia, schizoaffective disorder, psychotic&#xD;
             disorder not otherwise specified, bipolar disorder (with manic episode), borderline&#xD;
             personality disorder, or any neurocognitive disorder that may impair a reliable, safe&#xD;
             participation.&#xD;
&#xD;
          -  Current suicidal ideation.&#xD;
&#xD;
          -  Current active substance use disorder other than alcohol or tobacco.&#xD;
&#xD;
        EXCLUSION CRITERIA: Medications/Therapies&#xD;
&#xD;
          -  Currently prescribed or used within past week: doxazosin or other alpha1 noradrenergic&#xD;
             antagonist (e.g., prazosin, terazosin).&#xD;
&#xD;
          -  Currently prescribed or used within past week: substances with stimulant properties&#xD;
             (e.g., d-amphetamine, methylphenidate, ephedra, pseudoephedrine).&#xD;
&#xD;
          -  Currently prescribed or used within past week: Sildenafil (Viagra), tadalafil&#xD;
             (Cialis), and vardenafil (Levitra).&#xD;
&#xD;
          -  Currently prescribed or used within past week: beta-blockers (e.g., propanolol),&#xD;
             alpha2 agonists (e.g., clonidine, guanfacine, dexmedetomidine), and serotonin and&#xD;
             norepinephrine reuptake inhibitors (SNRI) (e.g., venlafaxine, duloxetine, atomoxetine,&#xD;
             viloxazine).&#xD;
&#xD;
          -  Currently used daily or used within past week: alpha1 agonists (e.g., midodrine,&#xD;
             metaraminol, oxymetazoline, phenylephrine).&#xD;
&#xD;
          -  Currently used daily or used within past week: Benzodiazepines (e.g., diazepam,&#xD;
             chlordiazepoxide, lorazepam, clonazepam, alprazolam), zolpidem (Ambien), zaleplon&#xD;
             (Sonata), zopiclone (Imovane), eszopiclone (Lunesta), doxepin (Silenor).&#xD;
&#xD;
          -  Currently prescribed and used daily or used within past 2 weeks: Trazodone.&#xD;
&#xD;
          -  Currently prescribed or used within 2 weeks: Disulfiram (Antabuse).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John J Curtin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://arc.psych.wisc.edu</url>
    <description>Dr. John Curtin's Addiction Research Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <results_first_submitted>February 23, 2021</results_first_submitted>
  <results_first_submitted_qc>March 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2021</results_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>Stress</keyword>
  <keyword>Norepinephrine</keyword>
  <keyword>Doxazosin</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Startle Potentiation</keyword>
  <keyword>Relapse</keyword>
  <keyword>Adrenergic Antagonists</keyword>
  <keyword>Surrogate Endpoint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available online upon study completion at the Open Science Framework: https://osf.io</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02989493/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled via community advertisement and clinical referral.</recruitment_details>
      <pre_assignment_details>61 participants were consented, passed medical screening, and were assigned to a drug group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxazosin</title>
          <description>Participants receive 8 weeks of doxazosin (8mg target dose).&#xD;
Doxazosin: Doxazosin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive 8 weeks of matched placebo.&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxazosin</title>
          <description>Participants receive 8 weeks of doxazosin (8mg target dose).&#xD;
Doxazosin: Doxazosin</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive 8 weeks of matched placebo.&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>self report age</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="11.9"/>
                    <measurement group_id="B2" value="39.7" spread="10.8"/>
                    <measurement group_id="B3" value="42.5" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All participants were enrolled in Madison, WI, USA</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Startle Potentiation During Stress Reactivity Task</title>
        <description>Startle potentiation is used to study anxiety and fear with No-shock, Predictable-shock, Unpredictable-shock (NPU) task; a common, well-validated laboratory stressor task. In the Predictable condition of the NPU task, shocks are 100 percent predictable and occur at a consistent, known time. In the Unpredictable condition of the NPU task, shocks are fully unpredictable. A higher score on startle potentiation means a higher stress reactivity response for the given condition.</description>
        <time_frame>4 weeks</time_frame>
        <population>Although all 61 participants were able to provide TLFB data through the end of 8 weeks, the NPU task required that they attend a study visit at 4 weeks. 24 participants (10 in doxazosin, 13 in placebo) did not complete that study visit and so have data missing for this outcome measure. 1 (doxazosin) attended the visit but chose not to complete the NPU task. 2 participants (both placebo) completed NPU at this visit, but their NPU data was unusable for this analysis due to technical issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxazosin</title>
            <description>Participants receive 8 weeks of doxazosin (8mg target dose).&#xD;
Doxazosin: Doxazosin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive 8 weeks of matched placebo.&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Startle Potentiation During Stress Reactivity Task</title>
          <description>Startle potentiation is used to study anxiety and fear with No-shock, Predictable-shock, Unpredictable-shock (NPU) task; a common, well-validated laboratory stressor task. In the Predictable condition of the NPU task, shocks are 100 percent predictable and occur at a consistent, known time. In the Unpredictable condition of the NPU task, shocks are fully unpredictable. A higher score on startle potentiation means a higher stress reactivity response for the given condition.</description>
          <population>Although all 61 participants were able to provide TLFB data through the end of 8 weeks, the NPU task required that they attend a study visit at 4 weeks. 24 participants (10 in doxazosin, 13 in placebo) did not complete that study visit and so have data missing for this outcome measure. 1 (doxazosin) attended the visit but chose not to complete the NPU task. 2 participants (both placebo) completed NPU at this visit, but their NPU data was unusable for this analysis due to technical issues.</population>
          <units>microvolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unpredictable startle potentiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.25" spread="20.18"/>
                    <measurement group_id="O2" value="20.76" spread="23.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Predictable startle potentiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.22" spread="30.90"/>
                    <measurement group_id="O2" value="22.21" spread="35.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Any Heavy Drinking Days</title>
        <description>Timeline-followback (TLFB) was administered twice at 4 weeks and 8 weeks. Participants reported the number of drinks per day for each previous 30 day period. Any heavy drinking was scored &quot;yes&quot; if participant reported any days of heavy drinking (&gt; 4/3 standard drinks for men/women) during the total 8 week assessment period; &quot;no&quot; if no heavy drinking was reported</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxazosin</title>
            <description>Participants receive 8 weeks of doxazosin (8mg target dose).&#xD;
Doxazosin: Doxazosin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive 8 weeks of matched placebo.&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Any Heavy Drinking Days</title>
          <description>Timeline-followback (TLFB) was administered twice at 4 weeks and 8 weeks. Participants reported the number of drinks per day for each previous 30 day period. Any heavy drinking was scored &quot;yes&quot; if participant reported any days of heavy drinking (&gt; 4/3 standard drinks for men/women) during the total 8 week assessment period; &quot;no&quot; if no heavy drinking was reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Doxazosin</title>
          <description>Participants receive 8 weeks of doxazosin (8mg target dose).&#xD;
Doxazosin: Doxazosin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive 8 weeks of matched placebo.&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chest pains</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry vision</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea or diarrhea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="38" subjects_affected="15" subjects_at_risk="29"/>
                <counts group_id="E2" events="36" subjects_affected="17" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="25" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="30" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>General symptoms, nonspecific</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyurea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Priapism</sub_title>
                <description>This was only assessed in men</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E2" events="18" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Curtin</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-262-0387</phone>
      <email>jjcurtin@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

